IP Library Granted Patent US 8,460,932
Granted Patent B2
US 8,460,932 · App. 11/444,050 · Granted Jun 11, 2013

Method of treating a disorder by suicide gene therapy

Inventors: Pedro Lowenstein (Los Angeles, CA); Maria Castro (Los Angeles, CA)
Assignee: Cedars-Sinai Medical Center
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,460,932
App. No.
11/444,050
Granted
Jun 11, 2013
Kind
B2
Abstract

The present invention relates to a method of prolonging the expression of an exogenous gene in a cell transduced with the exogenous gene. The method comprises co-administration of the exogenous gene with a herpes virus gene, whereby such co-administration prolongs the expression of the exogenous gene in the transduced cell. The method is particularly useful as a means of effecting gene therapy.

Claims (16)

1. A method for the treatment of a tumor in an individual by suicide gene therapy, the method comprising:

co-administering an adenovirus expressing the suicide gene, encoding a cytotoxic pro-drug converting enzyme under the control of an expression control sequence, directly into the tumor of the individual, and a cytotoxic pro-drug that effectively treats the tumor in the individual; and

repeating the administration of said cytotoxic pro-drug to the individual, wherein said repeating is at three months or more after the co-administration, and

wherein the cytotoxic pro-drug comprises ganciclovir.

2. The method according to claim 1 , wherein said repeating the administration of said cytotoxic pro-drug is at, three months, four months, six months, eight months, ten months or twelve months or fractions thereof.

3. The method of claim 1 , wherein the suicide gene comprises HSV1-TK coding sequences.

4. The method of claim 1 , wherein the tumor is a brain glioma.

5. A method of increasing the effectiveness of a cytotoxic pro-drug in an individual in need thereof, the method comprising:

providing an adenovirus vector, encoding HSV1-TK under the control of an expression control sequence; and

co-administering, to the individual, the adenovirus vector with a first cycle of said cytotoxic pro-drug, said cytotoxic pro-drug being administered to the individual at additional cycles, wherein at least one cycle is at three months or more after the co-administration, wherein the cytotoxic pro-drug comprises ganciclovir.

6. A method of causing regression of tumor size in an individual in need thereof, the method comprising:

co-administering an adenovirus vector, encoding HSV1-TK under the control of an expression control sequence directly into said tumor of the individual, and ganciclovir, wherein said ganciclovir is administered to the individual at additional cycles, and at least one cycle is at three months or more after the co-administration.

7. A method for the treatment of a tumor in an individual by suicide gene therapy, the method comprising:

co-administrating an adenovirus vector, encoding HSV1-TK under the control of an expression control sequence directly into the tumor of the individual, and

ganciclovir to the individual; and

repeating the administration of said ganciclovir to the individual, wherein said repeating is at three months or more after the co-administration.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 15, 2016
From: CEDARS-SINAI MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039354/0476 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2006
From: LOWENSTEIN, PEDRO; CASTRO, MARIA
To: VICTORIA UNIVERSITY OF MANCHESTER, THE
Reel/Frame 017960/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2006
From: VICTORIA UNIVERSITY OF MANCHESTER, THE
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 017960/0508 →
Priority Claims (1)
GB 9924981.5 · Oct 21, 1999 · national
Continuity (3)
Division 10395287 · Mar 25, 2003
Continuation 09693970 · Oct 23, 2000
Related Publication 20060246038A1 · Nov 2, 2006